Allen A Mitchell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7636421/publications.pdf

Version: 2024-02-01

198 papers 15,563 citations

20759 60 h-index 120 g-index

206 all docs

206 docs citations

206 times ranked 12602 citing authors

#	Article	IF	Citations
1	Recent Patterns of Medication Use in the Ambulatory Adult Population of the United States. JAMA - Journal of the American Medical Association, 2002, 287, 337.	3.8	1,552
2	Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology. American Journal of Epidemiology, 2002, 155, 176-184.	1.6	1,107
3	Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. New England Journal of Medicine, 2006, 354, 579-587.	13.9	821
4	Folic Acid Antagonists during Pregnancy and the Risk of Birth Defects. New England Journal of Medicine, 2000, 343, 1608-1614.	13.9	689
5	Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. American Journal of Obstetrics and Gynecology, 2011, 205, 51.e1-51.e8.	0.7	587
6	First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. New England Journal of Medicine, 2007, 356, 2675-2683.	13.9	467
7	Use of over-the-counter medications during pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, 771-777.	0.7	331
8	Prevalence and characteristics of opioid use in the US adult population. Pain, 2008, 138, 507-513.	2.0	269
9	Recent Trends in Use of Herbal and Other Natural Products. Archives of Internal Medicine, 2005, 165, 281.	4.3	235
10	Multivitamin Supplementation and Risk of Brith Defects. American Journal of Epidemiology, 1999, 150, 675-682.	1.6	228
11	Maternal Medication Use and Risks of Gastroschisis and Small Intestinal Atresia. American Journal of Epidemiology, 2002, 155, 26-31.	1.6	223
12	Prepregnant weight in relation to risk of neural tube defects. JAMA - Journal of the American Medical Association, 1996, 275, 1089-1092.	3.8	222
13	Neural Tube Defects in Relation to Use of Folic Acid Antagonists during Pregnancy. American Journal of Epidemiology, 2001, 153, 961-968.	1.6	206
14	Lack of Relation of Oral Clefts to Diazepam Use during Pregnancy. New England Journal of Medicine, 1983, 309, 1282-1285.	13.9	205
15	EFFECT OF QUESTIONNAIRE DESIGN ON RECALL OF DRUG EXPOSURE IN PREGNANCY. American Journal of Epidemiology, 1986, 123, 670-676.	1.6	201
16	The Safety of Acetaminophen and Ibuprofen Among Children Younger Than Two Years Old. Pediatrics, 1999, 104, e39-e39.	1.0	193
17	Medications as a Potential Source of Exposure to Phthalates in the U.S. Population. Environmental Health Perspectives, 2009, 117, 185-189.	2.8	187
18	Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. American Journal of Medical Genetics, Part A, 2009, 149A, 1241-1248.	0.7	187

#	Article	IF	Citations
19	First trimester maternal medication use in relation to gastroschisis. Teratology, 1992, 45, 361-367.	1.8	179
20	A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin. New England Journal of Medicine, 1995, 333, 101-106.	13.9	170
21	Risk Factors for Persistent Pulmonary Hypertension of the Newborn. Pediatrics, 2007, 120, e272-e282.	1.0	163
22	Asthma Morbidity After the Short-Term Use of Ibuprofen in Children. Pediatrics, 2002, 109, e20-e20.	1.0	162
23	Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Research Part A: Clinical and Molecular Teratology, 2012, 94, 22-30.	1.6	151
24	Medication Use Among Children & Survey. Pediatrics, 2009, 124, 446-454.	1.0	148
25	Association of Vasoconstrictive Exposures with Risks of Gastroschisis and Small Intestinal Atresia. Epidemiology, 2003, 14, 349-354.	1.2	142
26	Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiology and Drug Safety, 2013, 22, 1013-1018.	0.9	140
27	Case-Control Study of Periconceptional Folic Acid Supplementation and Oral Clefts. American Journal of Epidemiology, 1996, 143, 1229-1234.	1.6	138
28	Identification of Phthalates in Medications and Dietary Supplement Formulations in the United States and Canada. Environmental Health Perspectives, 2012, 120, 379-384.	2.8	138
29	Use of topiramate in pregnancy and risk of oral clefts. American Journal of Obstetrics and Gynecology, 2012, 207, 405.e1-405.e7.	0.7	130
30	Systematic Identification of Drugs That Cause Birth Defects â€" A New Opportunity. New England Journal of Medicine, 2003, 349, 2556-2559.	13.9	127
31	Diarrhea in American Infants and Young Children in the Community Setting. Pediatric Infectious Disease Journal, 2006, 25, 2-7.	1.1	115
32	Periconceptional Use of Opioids and the Risk of Neural Tube Defects. Obstetrics and Gynecology, 2013, 122, 838-844.	1.2	115
33	Antihypertensive Medication Use During Pregnancy and the Risk of Cardiovascular Malformations. Hypertension, 2009, 54, 63-70.	1.3	114
34	Use of Antiepileptic Medications in Pregnancy in Relation to Risks ofÂBirth Defects. Annals of Epidemiology, 2011, 21, 842-850.	0.9	113
35	Birth Defects Related to Bendectin Use in Pregnancy. JAMA - Journal of the American Medical Association, 1981, 245, 2311.	3.8	101
36	Adverse Drug Reactions in Children Leading to Hospital Admission. Pediatrics, 1988, 82, 24-29.	1.0	98

#	Article	IF	CITATIONS
37	The Relation of Aspirin Use during the First Trimester of Pregnancy to Congenital Cardiac Defects. New England Journal of Medicine, 1989, 321, 1639-1642.	13.9	94
38	Demographic, reproductive, medical, and environmental factors in relation to gastroschisis. Teratology, 1992, 45, 353-360.	1.8	94
39	Cough and Cold Medication Use by US Children, 1999–2006: Results From the Slone Survey. Pediatrics, 2008, 122, e323-e329.	1.0	92
40	Risks and safety of pandemic $h1n1$ influenza vaccine in pregnancy: Birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine, 2013, 31, 5026-5032.	1.7	92
41	Selective Serotonin Reuptake Inhibitor Use and Risk of Gestational Hypertension. American Journal of Psychiatry, 2009, 166, 320-328.	4.0	89
42	Secular Changes in Sleep Position During Infancy: 1995-1998. Pediatrics, 2003, 111, 52-60.	1.0	88
43	Heparin Use as a Risk Factor for Intraventricular Hemorrhage in Low-Birth-Weight Infants. New England Journal of Medicine, 1986, 314, 1156-1160.	13.9	85
44	MATERNAL CIGARETTE SMOKING DURING PREGNANCY IN RELATION TO ORAL CLEFTS. American Journal of Epidemiology, 1990, 132, 926-932.	1.6	84
45	Trends and predictors of folic acid awareness and periconceptional use in pregnant women. American Journal of Obstetrics and Gynecology, 2005, 192, 121-128.	0.7	84
46	Management of Acute Otitis Media by Primary Care Physicians: Trends Since the Release of the 2004 American Academy of Pediatrics/American Academy of Family Physicians Clinical Practice Guideline. Pediatrics, 2007, 120, 281-287.	1.0	80
47	Maternal Alcohol Use in Relation to Selected Birth Defects. American Journal of Epidemiology, 1991, 134, 691-698.	1.6	77
48	Frequency of Bed Sharing and its Relationship to Breastfeeding. Journal of Developmental and Behavioral Pediatrics, 2004, 25, 141-149.	0.6	77
49	Changes in Sleep Position During Infancy. JAMA - Journal of the American Medical Association, 1998, 280, 336.	3.8	76
50	Risk of Gestational Hypertension in Relation to Folic Acid Supplementation during Pregnancy. American Journal of Epidemiology, 2002, 156, 806-812.	1.6	76
51	Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Research Part A: Clinical and Molecular Teratology, 2004, 70, 389-395.	1.6	74
52	Descriptive epidemiology of idiopathic clubfoot. American Journal of Medical Genetics, Part A, 2013, 161, 1569-1578.	0.7	72
53	Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction. Journal of Clinical Psychopharmacology, 2009, 29, 555-560.	0.7	70
54	Maternal vitamin A supplementation in relation to selected birth defects. Teratology, 1990, 42, 497-503.	1.8	69

#	Article	IF	CITATIONS
55	Safety of macrolides during pregnancy. American Journal of Obstetrics and Gynecology, 2013, 208, 221.e1-221.e8.	0.7	69
56	Risks to Children From Computed Tomographic Scan Premedication. JAMA - Journal of the American Medical Association, 1982, 247, 2385.	3.8	68
57	Nausea and vomiting in pregnancy: maternal characteristics and risk factors. Paediatric and Perinatal Epidemiology, 2006, 20, 270-278.	0.8	67
58	The impact of folic acid intake on the association among diabetes mellitus, obesity, and spina bifida. American Journal of Obstetrics and Gynecology, 2013, 209, 239.e1-239.e8.	0.7	66
59	Demographic and Reproductive Factors Associated with Hemifacial Microsomia. Cleft Palate-Craniofacial Journal, 2004, 41, 494-500.	0.5	64
60	Nonsteroidal Antiinflammatory Drugs in Late Pregnancy and Persistent Pulmonary Hypertension of the Newborn. Pediatrics, 2013, 131, 79-87.	1.0	64
61	Sensitivity and Specificity of Computerized Algorithms to Classify Gestational Periods in the Absence of Information on Date of Conception. American Journal of Epidemiology, 2007, 167, 633-640.	1.6	63
62	Herbal use before and during pregnancy. American Journal of Obstetrics and Gynecology, 2010, 202, 443.e1-443.e6.	0.7	63
63	Erythromycin use during pregnancy in relation to pyloric stenosis. American Journal of Obstetrics and Gynecology, 2002, 186, 288-290.	0.7	61
64	Selection Bias and the Use of Controls with Malformations in Case-Control Studies of Birth Defects. Epidemiology, 1999, 10, 238-241.	1.2	59
65	Use of herbal treatments in pregnancy. American Journal of Obstetrics and Gynecology, 2010, 202, 439.e1-439.e10.	0.7	59
66	Medications as a potential source of exposure to phthalates among women of childbearing age. Reproductive Toxicology, 2013, 37, 1-5.	1.3	59
67	Use of Decongestants During Pregnancy and the Risk of Birth Defects. American Journal of Epidemiology, 2013, 178, 198-208.	1.6	59
68	Is there epidemiologic evidence to support vascular disruption as a pathogenesis of gastroschisis?. American Journal of Medical Genetics, Part A, 2009, 149A, 1399-1406.	0.7	58
69	Safety of the 2010–11, 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Birt defects, spontaneous abortion, preterm delivery, and small for gestational age infants, a study from the cohort arm of VAMPSS. Vaccine, 2016, 34, 4443-4449.	h 1.7	58
70	Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. JAMA Psychiatry, 2020, 77, 1246.	6.0	58
71	Case-Crossover and Case-Time-Control Designs in Birth Defects Epidemiology. American Journal of Epidemiology, 2003, 158, 385-391.	1.6	57
72	The Use of Cisapride in Children. Journal of Pediatric Gastroenterology and Nutrition, 1999, 28, 529-533.	0.9	57

#	Article	IF	Citations
73	DRUG UTILIZATION AND REPORTED ADVERSE REACTIONS IN HOSPITALIZED CHILDREN. American Journal of Epidemiology, 1979, 110, 196-204.	1.6	55
74	Maternal exposure to statins and risk for birth defects: A caseâ€series approach. American Journal of Medical Genetics, Part A, 2008, 146A, 2701-2705.	0.7	55
75	Folic Acid Intake and Spina Bifida in the Era of Dietary Folic Acid Fortification. Epidemiology, 2011, 22, 731-737.	1.2	54
76	Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System. American Journal of Obstetrics and Gynecology, 2011, 204, S64-S68.	0.7	54
77	Birth defects in relation to Bendectin use in pregnancy. American Journal of Obstetrics and Gynecology, 1983, 147, 737-742.	0.7	53
78	Sleep Position of Low Birth Weight Infants. Pediatrics, 2003, 111, 633-640.	1.0	53
79	Racial/ethnic disparities in the diagnosis of otitis media in infancy. International Journal of Pediatric Otorhinolaryngology, 2004, 68, 795-804.	0.4	52
80	Maternal Exposure to Amoxicillin and the Risk of Oral Clefts. Epidemiology, 2012, 23, 699-705.	1.2	51
81	Infertility Treatment — More Risks and Challenges. New England Journal of Medicine, 2002, 346, 769-770.	13.9	50
82	Maternal Dietary Glycemic Intake and the Risk of Neural Tube Defects. American Journal of Epidemiology, 2010, 171, 407-414.	1.6	50
83	Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology, 2003, 14, 349-54.	1.2	48
84	Epidemiologic analysis of maternal factors and amniotic band defects. Birth Defects Research Part A: Clinical and Molecular Teratology, 2003, 67, 68-72.	1.6	47
85	Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: Exposure prevalence, preterm delivery, and specific birth defects. Vaccine, 2013, 31, 5033-5040.	1.7	46
86	Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects. Obstetrics and Gynecology, 2018, 132, 385-394.	1.2	46
87	Maternal caffeine consumption and risk of cardiovascular malformations. Birth Defects Research Part A: Clinical and Molecular Teratology, 2007, 79, 533-543.	1.6	45
88	Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiology and Drug Safety, 2005, 14, 837-842.	0.9	44
89	Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Research Part A: Clinical and Molecular Teratology, 2008, 82, 34-40.	1.6	44
90	Multivitamin supplementation and multiple births. , 1997, 71, 93-96.		41

#	Article	IF	CITATIONS
91	Validity of Parental Reporting of Recent Episodes of Acute Otitis Media: A Slone Center Office-based Research (SCOR) Network Study. Journal of the American Board of Family Medicine, 2007, 20, 160-163.	0.8	41
92	A study of adverse reaction algorithms in a drug surveillance program. Clinical Pharmacology and Therapeutics, 1985, 38, 183-187.	2.3	40
93	Recent patterns of drug use in newborn intensive care. Journal of Pediatrics, 1990, 116, 985-990.	0.9	40
94	First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiology and Drug Safety, 2014, 23, 1066-1075.	0.9	40
95	Maternal Exposure to Spermicides in Relation to Certain Birth Defects. New England Journal of Medicine, 1987, 317, 474-478.	13.9	39
96	Knowledge and Practices Relating to the 2004 Acute Otitis Media Clinical Practice Guideline. Pediatric Infectious Disease Journal, 2006, 25, 385-389.	1.1	39
97	Gestational hypertension in pregnancies supported by infertility treatments: role of infertility, treatments, and multiple gestations. Fertility and Sterility, 2007, 88, 438-445.	0.5	37
98	Antibiotics and oral contraceptive failure â€" a case-crossover study. Contraception, 2011, 83, 418-425.	0.8	37
99	Low maternal alcohol consumption during pregnancy and oral clefts in offspring: The Slone birth defects study. Birth Defects Research Part A: Clinical and Molecular Teratology, 2003, 67, 509-514.	1.6	36
100	Infant Sleep Position and Associated Health Outcomes. JAMA Pediatrics, 2003, 157, 469.	3.6	36
101	Use of Selective Serotonin-Reuptake Inhibitors During Pregnancy and the Risk of Clubfoot. Epidemiology, 2014, 25, 859-865.	1.2	36
102	Antifungal drugs and the risk of selected birth defects. American Journal of Obstetrics and Gynecology, 2008, 198, 191.e1-191.e7.	0.7	34
103	Asthma in pregnancy and its pharmacologic treatment. Annals of Allergy, Asthma and Immunology, 2010, 105, 110-117.	0.5	34
104	The management of propoxyphene poisoning. Journal of Pediatrics, 1974, 85, 98-100.	0.9	33
105	Use of Herbal/Natural Supplements According to Racial/Ethnic Group. Journal of Alternative and Complementary Medicine, 2006, 12, 555-561.	2.1	33
106	Assessment of Antihistamine Use in Early Pregnancy and Birth Defects. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 666-674.e1.	2.0	32
107	Maternal Hypertension, Medication Use, and Hypospadias in the National Birth Defects Prevention Study. Obstetrics and Gynecology, 2014, 123, 309-317.	1.2	32
108	Safety of the 2011–12, 2012–13, and 2013–14 seasonal influenza vaccines in pregnancy: Preterm delivery and specific malformations, a study from the case-control arm of VAMPSS. Vaccine, 2016, 34, 4450-4459.	1.7	32

7

#	Article	IF	Citations
109	Tolerability of oral xylitol solution in young children: Implications for otitis media prophylaxis. International Journal of Pediatric Otorhinolaryngology, 2007, 71, 89-94.	0.4	30
110	Maternal Cigarette, Alcohol, and Coffee Consumption in Relation to Risk of Clubfoot. Paediatric and Perinatal Epidemiology, 2015, 29, 3-10.	0.8	30
111	Periconceptional maternal fever, folic acid intake, and the risk for neural tube defects. Annals of Epidemiology, 2017, 27, 777-782.e1.	0.9	30
112	Increasing use of ADHD medications in pregnancy. Pharmacoepidemiology and Drug Safety, 2015, 24, 218-220.	0.9	28
113	Tdap Vaccination Coverage During Pregnancy — Selected Sites, United States, 2006–2015. Morbidity and Mortality Weekly Report, 2017, 66, 1105-1108.	9.0	28
114	Drug ingestions associated with miosis in comatose children. Journal of Pediatrics, 1976, 89, 303-305.	0.9	27
115	When a Randomised Controlled Trial is Needed to Assess Drug Safety The Case of Paediatric Ibuprofen. Drug Safety, 1995, 13, 15-24.	1.4	27
116	Maternal tea consumption during early pregnancy and the risk of spina bifida. Birth Defects Research Part A: Clinical and Molecular Teratology, 2012, 94, 756-761.	1.6	27
117	Xylitol Syrup for the Prevention of Acute Otitis Media. Pediatrics, 2014, 133, 289-295.	1.0	27
118	Seasonal Influenza Vaccination during Pregnancy and the Risks of Preterm Delivery and Small for Gestational Age Birth. Paediatric and Perinatal Epidemiology, 2014, 28, 498-509.	0.8	26
119	Antiherpetic Medication Use and the Risk of Gastroschisis: Findings from the National Birth Defects Prevention Study, 1997–2007. Paediatric and Perinatal Epidemiology, 2013, 27, 340-345.	0.8	25
120	Pseudoephedrine Use Among US Children, 1999-2006: Results From the Slone Survey. Pediatrics, 2008, 122, 1299-1304.	1.0	24
121	Maternal Genitourinary Infections and the Risk of Gastroschisis. American Journal of Epidemiology, 2014, 180, 518-525.	1.6	24
122	Medication Use in Pregnancy in Relation to the Risk of Isolated Clubfoot in Offspring. American Journal of Epidemiology, 2014, 180, 86-93.	1.6	24
123	Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997–2011. Birth Defects Research, 2019, 111, 613-620.	0.8	24
124	Maternal self-reported genital tract infections during pregnancy and the risk of selected birth defects. Birth Defects Research Part A: Clinical and Molecular Teratology, 2011, 91, 108-116.	1.6	22
125	Characteristics of Persistent Diarrhea in a Community-Based Cohort of Young US Children. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 52-58.	0.9	21
126	Special Considerations in Studies of Drug-induced Birth Defects. , 0, , 749-763.		20

#	Article	IF	CITATIONS
127	Signal generation and clarification: use of case-control data. Pharmacoepidemiology and Drug Safety, 2001, 10, 197-203.	0.9	20
128	Case–control studies for identifying novel teratogens. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2011, 157, 201-208.	0.7	20
129	Correcting for exposure misclassification using survival analysis with a time-varying exposure. Annals of Epidemiology, 2012, 22, 799-806.	0.9	20
130	Periconceptional folic acid and risk for neural tube defects among higher risk pregnancies. Birth Defects Research, 2019, 111, 1501-1512.	0.8	20
131	Vancomycin-associated shock and rash in newborn infants. Journal of Pediatrics, 1987, 111, 615-616.	0.9	19
132	A description of spina bifida cases and coâ€occurring malformations, 1976–2011. American Journal of Medical Genetics, Part A, 2014, 164, 432-440.	0.7	19
133	Title is missing!. Epidemiology, 2003, 14, 349-354.	1.2	18
134	Risk of Spina Bifida and Maternal Cigarette, Alcohol, and Coffee Use during the First Month of Pregnancy. International Journal of Environmental Research and Public Health, 2013, 10, 3263-3281.	1.2	18
135	Preconceptional Iron Intake and Gestational Diabetes Mellitus. International Journal of Environmental Research and Public Health, 2016, 13, 525.	1.2	18
136	Ovulation induction and risk of neural tube defects. Lancet, The, 1994, 344, 445-446.	6.3	17
137	Periconceptional Multivitamin Use and Infant Birth Weight Disparities. Annals of Epidemiology, 2010, 20, 233-240.	0.9	17
138	CDC Grand Rounds: Understanding the Causes of Major Birth Defects â€" Steps to Prevention. Morbidity and Mortality Weekly Report, 2015, 64, 1104-1107.	9.0	17
139	Methylenetetrahydrofolate Reductase Polymorphisms and the Risk of Gestational Hypertension. Epidemiology, 2005, 16, 628-634.	1.2	16
140	Maternal dietary glycaemic intake during pregnancy and the risk of birth defects. Paediatric and Perinatal Epidemiology, 2011, 25, 340-346.	0.8	16
141	Validity of maternal recall of gestational age and weight at birth: Comparison of structured interview and medical records. Pharmacoepidemiology and Drug Safety, 2019, 28, 269-273.	0.9	16
142	Oral Retinoids. Drug Safety, 1992, 7, 79-85.	1.4	15
143	Vasoactive exposures during pregnancy and risk of microtia. Birth Defects Research Part A: Clinical and Molecular Teratology, 2013, 97, 53-59.	1.6	15
144	Influenza vaccine safety in pregnancy: can we identify exposures?. Pharmacoepidemiology and Drug Safety, 2013, 22, 33-39.	0.9	15

#	Article	IF	Citations
145	Use of a Job-Exposure Matrix to Assess Occupational Exposures in Relation to Birth Defects. Journal of Occupational and Environmental Medicine, 2000, 42, 693-703.	0.9	15
146	Are hydantoins (phenytoins)human teratogens?. Journal of Pediatrics, 1977, 90, 673-674.	0.9	14
147	Case-Control Study of Vitamin Supplementation and Neural Tube Defects Consideration of Potential Confounding by Lifestyle Factors. Annals of the New York Academy of Sciences, 1993, 678, 276-283.	1.8	13
148	Association between prepregnancy maternal body mass index and the risk of having an infant with a congenital diaphragmatic hernia. Birth Defects Research Part A: Clinical and Molecular Teratology, 2003, 67, 73-76.	1.6	13
149	Proton-Pump Inhibitors and Birth Defects â€" Some Reassurance, but More Needed. New England Journal of Medicine, 2010, 363, 2161-2163.	13.9	13
150	Impact of Periconceptional Use of Nitrosatable Drugs on the Risk of Neural Tube Defects. American Journal of Epidemiology, 2015, 182, 675-684.	1.6	12
151	Fetal risk from ACE inhibitors in the first trimester. BMJ: British Medical Journal, 2011, 343, d6667-d6667.	2.4	11
152	Can folic acid protect against congenital heart defects in down syndrome?. Birth Defects Research Part A: Clinical and Molecular Teratology, 2006, 76, 714-717.	1.6	10
153	Decongestant use during pregnancy and its association with preterm delivery. Birth Defects Research Part A: Clinical and Molecular Teratology, 2010, 88, 715-721.	1.6	10
154	Influenza Vaccination Coverage During Pregnancy — Selected Sites, United States, 2005–06 Through 2013–14 Influenza Vaccine Seasons. Morbidity and Mortality Weekly Report, 2016, 65, 1370-1373.	9.0	10
155	An Updated Medical Position Statement of the North American Society for Pediatric Gastroenterology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition, 2000, 31, 232-233.	0.9	8
156	Accutane and pregnancy. Journal of the American Academy of Dermatology, 2003, 49, 1201-1202.	0.6	8
157	Gulf war veterans and hemifacial microsomia. Birth Defects Research Part A: Clinical and Molecular Teratology, 2005, 73, 50-52.	1.6	8
158	Drug certainty-response in interview-based studies. Pharmacoepidemiology and Drug Safety, 2011, 20, 1210-1216.	0.9	8
159	Predictors of recall certainty of dates of analgesic medication use in pregnancy. Pharmacoepidemiology and Drug Safety, 2013, 22, 25-32.	0.9	8
160	Association of Clomiphene and Assisted Reproductive Technologies With the Risk of Neural Tube Defects. American Journal of Epidemiology, 2016, 183, 977-987.	1.6	8
161	Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. Birth Defects Research, 2018, 110, 579-586.	0.8	8
162	Studies of Drug-Induced Birth Defects. , 0, , 501-514.		7

#	Article	IF	CITATIONS
163	PRESCRIPTION MEDICATION SHARING. American Journal of Public Health, 2008, 98, 1926-1927.	1.5	7
164	Trends in firstâ€trimester nausea and vomiting of pregnancy and use of select treatments: Findings from the National Birth Defects Prevention Study. Paediatric and Perinatal Epidemiology, 2021, 35, 57-64.	0.8	7
165	Are Cyclooxygenase-2 Inhibitors Being Taken Only by Those Who Need Them?. Archives of Internal Medicine, 2005, 165, 1066.	4.3	6
166	Vitamin, Fluoride, and Iron Use among US Children Younger than 12 Years of Age: Results from the Slone Survey 1998-2007. Journal of the American Dietetic Association, 2011, 111, 285-289.	1.3	6
167	Tetanus, diphtheria, and pertussis vaccine (Tdap) in pregnancy and risk of major birth defects in the offspring. Birth Defects Research, 2020, 112, 393-403.	0.8	6
168	Analyses and reanalyses of epidemiologic data: Learning lessons and maintaining perspective. Teratology, 1992, 46, 209-211.	1.8	5
169	Oseltamivir exposure in pregnancy and the risk of specific birth defects. Birth Defects Research, 2019, 111, 1479-1486.	0.8	5
170	Maternal exposure to hydroxychloroquine and birth defects. Birth Defects Research, 2021, 113, 1245-1256.	0.8	5
171	Teratogens and the Dermatologist New Knowledge, Responsibilities, and Opportunities. Archives of Dermatology, 1991, 127, 399.	1.7	4
172	The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies., 0,, 539-552.		4
173	Folic acid antagonist use before and during pregnancy and risk for selected birth defects. Birth Defects Research, 2020, 112, 1526-1540.	0.8	4
174	Total bilirubin level in relation to excipients in parenteral morphine sulfate administered to seriously ill newborn infants. Paediatric and Perinatal Epidemiology, 1994, 8, 401-410.	0.8	3
175	A Response to the Commentary "Should We Consider a Subject's Knowledge of the Etiologic Hypothesis in the Analysis of Case-Control Studies?". American Journal of Epidemiology, 1995, 141, 297-298.	1.6	3
176	Xylitol Prophylaxis for Acute Otitis Media:Tout de Suite?. Pediatrics, 1998, 102, 974-975.	1.0	3
177	Prenatal Prescription of Macrolide Antibiotics and Infantile Hypertrophic Pyloric Stenosis. Obstetrics and Gynecology, 2003, 101, 816.	1.2	3
178	Prenatal prescription of macrolide antibiotics and infantile hypertrophic pyloric stenosis. Obstetrics and Gynecology, 2003, 101, 816.	1.2	2
179	Oral Dexamethasone for Mild Croup. New England Journal of Medicine, 2004, 351, 2768-2769.	13.9	2
180	Post-marketing surveillance using pharmacy-based cohorts: results of a pilot study. Pharmacoepidemiology and Drug Safety, 2005, 14, 289-295.	0.9	2

#	Article	lF	CITATIONS
181	Prone to Sleep, Prone to Pyloric Stenosis?. Epidemiology, 2006, 17, 136-137.	1.2	2
182	Application of data screening to drug exposure in large risk factor studies of birth defects. Birth Defects Research Part A: Clinical and Molecular Teratology, 2015, 103, 713-717.	1.6	2
183	Immunization surveillance systems for pregnant women. Pharmacoepidemiology and Drug Safety, 2015, 24, 669-669.	0.9	2
184	An application of data mining to identify potential risk factors for anophthalmia and microphthalmia. Paediatric and Perinatal Epidemiology, 2018, 32, 545-555.	0.8	2
185	Risk factors for congenital microcephaly in the preâ€Zika era. Birth Defects Research, 2019, 111, 96-118.	0.8	2
186	Periconceptional nonsteroidal antiâ€inflammatory drug use, folic acid intake, and the risk of spina bifida. Birth Defects Research, 2021, 113, 1257-1266.	0.8	2
187	Periconceptional Folic Acid Exposure and Risk of Occurrent Neural Tube Defects. Obstetrical and Gynecological Survey, 1993, 48, 528-529.	0.2	1
188	Analyses and reanalyses of epidemiologic data: Learning lessons and maintaining perspective. Teratology, 1994, 49, 167-168.	1.8	1
189	Response to Hook. Teratology, 1994, 49, 171-171.	1.8	1
190	Toh et al. Respond to "Compromise or Compromising?". American Journal of Epidemiology, 2007, 167, 644-645.	1.6	1
191	Xylitol to Prevent Acute Otitis Media. Pediatric Infectious Disease Journal, 2007, 26, 863-864.	1.1	1
192	"Phthalates― Kelley et al. Respond. Environmental Health Perspectives, 2012, 120, .	2.8	1
193	Comments on: Are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin. Pharmacoepidemiology and Drug Safety, 2014, 23, 439-439.	0.9	1
194	Multivitamin supplementation and multiple births. American Journal of Medical Genetics Part A, 1997, 71, 93-96.	2.4	1
195	Reply to Journal Club Roundtable. American Journal of Obstetrics and Gynecology, 2013, 209, 72.	0.7	0
196	The Authors Respond. Epidemiology, 2015, 26, e35-e36.	1.2	0
197	Use of vasoactive medications in pregnancy and the risk of stillbirth among birth defect cases. Birth Defects Research, 2022, , .	0.8	0
198	Maternal use of cough medications during early pregnancy and selected birth defects: a US multisite, case–control study. BMJ Open, 2021, 11, e053604.	0.8	0